Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1836P - Bacteraemia in cancer patients: An adverse prognostic factor and the relationship with chemotherapy


17 Sep 2020


E-Poster Display


Supportive Care and Symptom Management

Tumour Site


Filipa Macedo


Annals of Oncology (2020) 31 (suppl_4): S988-S1017. 10.1016/annonc/annonc291


F. Macedo, J. Monteiro, A.R. Monteiro, R. Félix Soares, T. Cunha Pereira, N. Bonito, G. Sousa

Author affiliations

  • Medical Oncology Department, Instituto Portugues Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), 3000-075 - Coimbra/PT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1836P


Bloodstream infection is a cause of morbi-mortality in cancer patients. The study aimed to clarify if bacteraemia in cancer patients is associated with higher mortality rates and to alert the community to this emerging problem.


The authors collected every cancer patient hospitalized in our cancer centre, who developed bacteraemia during their stay in hospital or at admission in the last 9 years. Data was treated with SPSS (t-student test, pearson correlation coefficient, bivariate analysis and Kaplan-Meier Curve). P values <0.05 were considered to be statistically significant.


A total of 204 bloodstream infections were reported, with positive cultural isolations. Almost half of the patients had gastrointestinal cancer (49%), followed by breast cancer (15,5%). Males were predominant (54,4%) and the median age was 66 years old. Catheter totally implanted (CTI) was responsible in 38,7% of the cases, and 28,9% had no identified focus. The responsible microorganism was E. coli in 24,5%, followed by S. aureus in 14,7% of the infections. From all bacteria, 20,5% were multidrug-resistant bacteria and 48% were resistant to at least one antibiotic. S. aureus was meticilin-resistent in 37% of infections and 4% were carbapenemase producing organisms. From all patients included in the study, 61,5% received chemotherapy the month before the infection. The survival of the patients that received chemotherapy was significantly different from patients that did not, t(203)=2,06, P=0,04. Chemotherapy the month before was correlated with lower survival rates, r(203)=-0,15, P=0,03, and Kaplan Meyer curve showed a tendency to statistical significance (P=0,06). The stage of the oncologic disease was not associated with the mortality of the patient (P>0,05). The infection contributed or was the cause of death in 45% of the patients. The 3-month mortality rate of the patients that had bacteraemia was 74,5%.


There are no guidelines regarding prescription of antimicrobial therapy in cancer patients or in palliative care. Three quarters of the cancer patients that suffer from bacteraemia died within 3 months, and active chemotherapy treatment was associated with lower survival rates. CTI was the main source of infection.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.